Philip Grant

Publications

• When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Grant PM, Zolopa AR. Curr HIV/AIDS Rep. 2012; 9 (3): 251-8
• Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. AIDS. 2011; 25 (2): 211-20
• Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Grant PM, Aberg JA, Zolopa AR. Clin Infect Dis. 2010; 51 (8): 984-5; author reply 987-9
• International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR. Antimicrob Agents Chemother. 2010; 54 (4): 1520-5
• Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. Grant PM, Zolopa AR. Curr Opin Investig Drugs. 2010; 11 (8): 901-10
• Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. Antimicrob Agents Chemother. 2010; 54 (6): 2473-9
• Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. Grant PM, Komarow L, Andersen J, Sereti I, Pahwa S, Lederman MM, Eron J, Sanne I, Powderly W, Hogg E, Suckow C, Zolopa A. PLoS One. 2010; 5 (7): e11416
• Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Grant P, Zolopa A. Curr HIV/AIDS Rep. 2009; 6 (2): 63-7
• Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Grant P, Taylor J, Cain P, Short W, Gallant J, Farthing C, Thal G, Coakley E, Zolopa A. Clin Infect Dis. 2009; 48 (5): 680-2
• Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. J Clin Virol. 2009; 46 (4): 305-8
• The use of resistance testing in the management of HIV-1-infected patients. Grant PM, Zolopa AR. Curr Opin HIV AIDS. 2009; 4 (6): 474-80
• Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Grant P, Zolopa A. J HIV Ther. 2008; 13 (2): 36-9
• Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores. Grant P, Wong EC, Rode R, Shafer R, De Luca A, Nadler J, Hawkins T, Cohen C, Harrington R, Kempf D, Zolopa A. Antimicrob Agents Chemother. 2008; 52 (11): 4050-6